Silas Inman, Senior Vice President, Content, joined MJH Life Sciences™ in early 2011 as one of the company's first web editors. In this position, he built OncLive.com from a fledgling web platform to a leading source of oncology news for community oncologists via in-depth reporting of breaking news from major medical conferences and the launch of OncLive® TV.
Throughout his tenure at MJH, Silas has been accountable for several organic launches of highly successful brands, including Targeted Oncology™ and NeurologyLive®, and for quickly transforming acquisitions into high-functioning business units. Prior to joining MJH, Silas, who attended Eastern Michigan University, was an EMT, frontend web developer, and social media/SEO expert. Follow him on Twitter @SilasInman or email him at sinman@mjhlifesciences.com
Juno Accelerates Development of JCAR017, Halts JCAR015
March 2nd 2017Juno therapeutics has shifted its focus toward the development of JCAR017 for relapsed/refractory diffuse large B-cell lymphoma after a series of toxicity-related setbacks culminated in the need to halt the development of JCAR015.
Read More
Prophylactic Letermovir Limits CMV Infections Post-Transplantation
February 27th 2017Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.
Read More
Vaccine Limits Herpes Zoster Infections Following Stem Cell Transplant
February 25th 2017Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.
Read More
Nab-Paclitaxel Paired With Anti-PD-L1 Immunotherapies in TNBC Studies
February 8th 2017Combination regimens that pair nab-paclitaxel with PD-L1 checkpoint blockade immunotherapy agents are emerging as a robust area of investigation in triple-negative breast cancer, bolstered by clinical trial results that establish the chemotherapeutic agent as an effective partner for other therapies.
Read More
FDA Grants Priority Review to Frontline Pembrolizumab for Urothelial Carcinoma
February 4th 2017The FDA has granted a priority review to pembrolizumab as a treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, according to Merck, the developer of the PD-1 inhibitor.
Read More
EC Approves Frontline Pembrolizumab for PD-L1+ Metastatic NSCLC
February 1st 2017The European Commission has expanded the indication for pembrolizumab to include the frontline treatment of patients with metastatic non–small cell lung cancer that expresses PD-L1 on ≥50% of cells and does not harbor an EGFR or ALK mutation.
Read More
Frontline Immunotherapy Combo Setbacks Strike NSCLC
January 21st 2017Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.
Read More
FDA Approves Ibrutinib for Marginal Zone Lymphoma
January 19th 2017The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.
Read More
FDA Grants Priority Review to Frontline Pembrolizumab Combo for NSCLC
January 11th 2017The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab in combination with pemetrexed plus carboplatin as a treatment for patients with metastatic or advanced non-squamous non–small cell lung cancer, regardless of PD-L1 expression and without EGFR or ALK mutations.
Read More
Nab-Paclitaxel/Carboplatin Doublet Superior in Phase II tnAcity Trial
December 11th 2016The combination of nab-paclitaxel and carboplatin reduced the risk of progression or death by 40% compared with 2 other chemotherapy doublets as a frontline therapy for patients with metastatic triple-negative breast cancer.
Read More
Pembrolizumab Shows Durable Responses in Heavily Pretreated TNBC
December 10th 2016Treatment with pembrolizumab continued to show a consistent durable benefit with an additional year of follow-up for heavily pretreated patients with recurrent PD-L1-positive metastatic triple-negative breast cancer.
Read More
New Mechanism of Action Results Renew Interest in Eribulin
December 9th 2016There has been renewed interest in eribulin mesylate following its FDA approval for advanced or unresectable liposarcoma and with the introduction of a growing body of preclinical work suggesting the agent has a novel anti–mesenchymal mechanism of action.
Read More
Buparlisib Combo Modestly Effective in Pretreated HR+ Breast Cancer
December 8th 2016Median progression-free survival was improved by 2.1 months with the addition of the pan-PI3K inhibitor buparlisib to fulvestrant for women with HR-positive/HER2-negative advanced breast cancer who received a prior aromatase inhibitor and progressed on or after an mTOR inhibitor.
Read More